期刊
ANNALS OF MEDICINE
卷 40, 期 6, 页码 444-455出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/07853890801908903
关键词
blood and marrow transplantation; chronic myeloid leukemia; HLA-mismatched
资金
- New Century Excellent Talents in University [NECT-04-0011]
- Scientific Research Fund for Capital Medicine Development [2006-1010]
- HI-tech research development program of China [2006AA02Z4A0]
- Program for Innovative Research Team in University [IRT0702]
Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only proven curative therapy for chronic myeloid leukemia (CML), but lack of human leukocyte antigen (HLA)-matched sibling or unrelated donors has restricted its application. Recently, we developed an effective method for haploidentical allo-HSCT achieving comparable outcomes to HLA-identical transplantation. Aim. To evaluate the outcomes of CML patients who underwent haploidentical allo-HSCT. Methods. Ninety-three patients were treated with a modified busulfan (BU)/cyclophosphamide (CY)2 regimen, including antithymocyte globulin followed by unmanipulated blood and marrow transplantation. Results. Our data showed that the cumulative incidence of acute graft-versus-host disease (GVHD) was 64.52%, and grade III-IV was 26.45%, 61.79% had chronic GVHD, and 28.93% had extensive chronic GVHD. Non-relapse mortality varied at 8.72% (100 days), 20.72% (1 year) and 20.72% (2 years). Probability of 1-year and 4-year leukemia-free survival was similar in chronic phase (CP) 1, CP2/CR2, accelerated phase, and blast crisis patients. Probability of 4-year overall survival varied as 76.5% (CP1), 85.7% (CP2/CR2), 73.3% (accelerated phase), and 61.5% (blast crisis). Multivariate analysis indicated that factors affecting transplantation outcomes were HLA-B+DR mismatches versus others for II-III acute GVHD and III-IV acute GVHD, the stage of disease at transplantation for relapse, and the time from diagnosis to transplantation for leukemia-free survival, overall survival, and transplantation-related mortality. In our protocol, survival of HSCT for advanced CML was similar to stable stage. Conclusions. For patients lacking an HLA-identical related donor, haploidentical relatives are alternative HSCT donors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据